ALX Oncology Unveils Promising Results from Aspen-05 Study: Evorpacept in Combination with Azacitidine and Venetoclax Shows Tolerability and Early Efficacy in Acute Myeloid Leukemia Patients
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax Antileukemic Activity Demonstrated ALX Oncology recently announced the initial data from the ASPEN-05 study, showcasing promising antileukemic activity in patients with both relapsed/refractory and newly diagnosed Acute Myeloid Leukemia (AML). No Observations of Cytopenias or Maximum Tolerated Dose The…